The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Breaking news from the ALCYONE study of VMP plus daratumumab for NDMM
Velcade (bortezomib)-melphalan-prednisone (VMP) is the standard of care for patients with transplant ineligible newly diagnosed multiple myeloma (NDMM). However, breaking results from the ongoing Phase III ALCYONE study (NCT02195479) have shown that the addition of daratumumab, a human IgGκ anti-CD38 monoclonal antibody, to this regimen could revolutionize the treatment of NDMM. In this exciting interview, filmed at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, Maria Victoria Mateos, MD, PhD, of University Hospital of Salamanca, Salamanca, Spain, discusses the game-changing results of the study, including the impressive data on progression-free survival, complete response rates and minimal residual disease negativity. Read more about the results of the study here: https://ash.confex.com/ash/2017/webprogram/Paper109143.html
